These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37156118)

  • 1. Targeting non-coding RNAs in sEVs: The biological functions and potential therapeutic strategy of diabetic cardiomyopathy.
    Ding N; Yin Z; Chen C
    Biomed Pharmacother; 2023 Jul; 163():114836. PubMed ID: 37156118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological Functions and Clinical Prospects of Extracellular Non-Coding RNAs in Diabetic Cardiomyopathy: an Updated Review.
    Yin Z; Chen C
    J Cardiovasc Transl Res; 2022 Jun; 15(3):469-476. PubMed ID: 35175553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy.
    Mathur P; Rani V
    Curr Gene Ther; 2021; 21(4):313-326. PubMed ID: 33719971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal microRNAs: potential targets for the prevention and treatment of diabetic cardiomyopathy.
    Zhang T; Gao Z; Chen K
    J Cardiol; 2022 Nov; 80(5):423-431. PubMed ID: 35000826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy.
    Pant T; Dhanasekaran A; Fang J; Bai X; Bosnjak ZJ; Liang M; Ge ZD
    BMC Cardiovasc Disord; 2018 Oct; 18(1):197. PubMed ID: 30342478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Non-coding RNA in Diabetic Cardiomyopathy.
    Xia L; Song M
    Adv Exp Med Biol; 2020; 1229():181-195. PubMed ID: 32285412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of non-coding RNA in diabetic cardiomyopathy.
    Yao X; Huang X; Chen J; Lin W; Tian J
    Cardiovasc Diabetol; 2024 Jun; 23(1):227. PubMed ID: 38951895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial Dysfunction and Diabetic Cardiomyopathy.
    Wang M; Li Y; Li S; Lv J
    Front Endocrinol (Lausanne); 2022; 13():851941. PubMed ID: 35464057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-coding RNA-mediated endothelial-to-mesenchymal transition in human diabetic cardiomyopathy, potential regulation by DNA methylation.
    Wang E; Chen S; Wang H; Chen T; Chakrabarti S
    Cardiovasc Diabetol; 2023 Nov; 22(1):303. PubMed ID: 37924123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The study of the mechanism of non-coding RNA regulation of programmed cell death in diabetic cardiomyopathy.
    Zhang B; Wu H; Zhang J; Cong C; Zhang L
    Mol Cell Biochem; 2024 Jul; 479(7):1673-1696. PubMed ID: 38189880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetics in diabetic cardiomyopathy.
    Ma X; Mei S; Wuyun Q; Zhou L; Sun D; Yan J
    Clin Epigenetics; 2024 Apr; 16(1):52. PubMed ID: 38581056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNAs and miRs as epigenetic signatures in diabetic cardiac fibrosis: new advances and perspectives.
    Tao H; Song ZY; Ding XS; Yang JJ; Shi KH; Li J
    Endocrine; 2018 Nov; 62(2):281-291. PubMed ID: 30054866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the programmed cell death (PCD) signaling mechanism with natural substances for the treatment of diabetic cardiomyopathy (DCM).
    Xuan X; Zhang S
    Phytother Res; 2023 Dec; 37(12):5495-5508. PubMed ID: 37622685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological Effects of Exosomes in Mediating Diabetic Cardiomyopathy.
    Salem ESB; Fan GC
    Adv Exp Med Biol; 2017; 998():113-138. PubMed ID: 28936736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy.
    Dhar A; Venkadakrishnan J; Roy U; Vedam S; Lalwani N; Ramos KS; Pandita TK; Bhat A
    Ther Adv Cardiovasc Dis; 2023; 17():17539447231210170. PubMed ID: 38069578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of caveolin as a target in the prevention and treatment of diabetic cardiomyopathy.
    Xia W; Li X; Wu Q; Xu A; Zhang L; Xia Z
    Front Immunol; 2022; 13():951381. PubMed ID: 36405687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-coding RNA involvement in the pathogenesis of diabetic cardiomyopathy.
    Zhang W; Xu W; Feng Y; Zhou X
    J Cell Mol Med; 2019 Sep; 23(9):5859-5867. PubMed ID: 31240820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs.
    Macvanin MT; Gluvic Z; Radovanovic J; Essack M; Gao X; Isenovic ER
    Front Endocrinol (Lausanne); 2023; 14():1124613. PubMed ID: 36950696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative stress signaling in the pathogenesis of diabetic cardiomyopathy and the potential therapeutic role of antioxidant naringenin.
    Xu N; Liu S; Zhang Y; Chen Y; Zuo Y; Tan X; Liao B; Li P; Feng J
    Redox Rep; 2023 Dec; 28(1):2246720. PubMed ID: 37747066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics.
    Jakubik D; Fitas A; Eyileten C; Jarosz-Popek J; Nowak A; Czajka P; Wicik Z; Sourij H; Siller-Matula JM; De Rosa S; Postula M
    Cardiovasc Diabetol; 2021 Feb; 20(1):55. PubMed ID: 33639953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.